Skip to main content
. 2022 Mar 28;40(19):2781–2789. doi: 10.1016/j.vaccine.2022.03.030

Table 1.

The three main model scenarios with different combinations of model input values.

Scenario Protection period Efficacy against cases Efficacy against hospitalization COVID-19 case incidence COVID-19 hospitalization
incidence
Vaccine attributable myocarditis/pericarditis death rate
Scenario 1 6 months 90% 90% July 10, 2021 rate July 10, 2021 rate 0%
Scenario 2 (Most Likely) 6 months 70% 80% 10× July 10, 2021 rate 4× July 10,2021 rate 0%
Scenario 3 (Worst-Case) 6 months 70% 80% July 10, 2021 rate July 10, 2021 rate 0.002%